Qiagen (QGEN) FY Conference June 09, 2025 09:00 AM ET Speaker0 Hi, good morning, everyone. I'm Matt Sykes, Life Science Tools and Diagnostics Analyst at Goldman Sachs. I have the pleasure of being joined by Roland Saker, CFO and John Gallardi, Head of IR. Roland, John, thanks for being here. Speaker1 Thank you. Speaker2 Thank you. Speaker0 Maybe we could start out, just given the current environment we're in, which is continues to be challenging, maybe just talk through sort of the durability of your end ma ...

证券代码：300009 证券简称：安科生物 安徽安科生物工程（集团）股份有限公司 投资者关系活动记录表 答：公司积极建设符合 FDA、欧盟认证的生产线，目前 正在进行相关验证和数据整理的工作，此外公司拥有一支专 业的国际贸易团队，与国外的经销商和代理商也积极沟通， 以推动产品在海外市场的商业化。由于目前在研或合作的创 新药品种仍处于临床阶段，公司会根据相关试验数据的结 果，规划对外合作。 问 4：公司布局的 mRNA 药物目前进展如何？ 答：根据世界卫生组织（WHO）数据，2023 年全球 HPV 感染者总数超过 6.3 亿人，世界卫生组织（WHO）指出，80% 的宫颈癌病例与未筛查的 HPV 持续感染有关，宫颈癌在全球 女性癌症病死率中排名第二，是女性第四大常见癌症，目前 国内外尚无治疗型 HPV 疫苗上市。公司参股合肥阿法纳公司 并与其进行研发合作，布局 mRNA 药物领域。公司与阿法纳 公司共同研发的用于治疗 HPV 肿瘤和癌前病变的 AFN0328 注 射液，其适应症为治疗 HPV16/18 感染相关的子宫颈癌、肛 门癌、外阴癌、阴道癌、阴茎癌、头颈部癌以及 HPV16 和/ 或 HPV18 相关宫颈 ...

本报记者 杨天悦 踏入首钢一高炉·SoReal科幻乐园，游人仿佛直接穿越到赛博科幻与传统文化交织的奇幻世界，浓浓的 科技感和"未来风"扑面而来。雄伟壮观的高炉建筑基底融合顶尖前沿科技技术，为市民游客带来全沉浸 式的太空探索主题科幻综合体。曾经的百年工业遗址迎来"新生"，成为京城休闲娱乐版图中"科技+文化 +消费"融合的新标杆。 据介绍，科幻乐园中不仅有可以互动体验的未来科技乐园和体育电竞赛场，也有让观众大饱眼福的主题 秀场和艺术展览；"齐天号"太空星舰主题区中，涵盖太空模拟驾驶、VR人机对战、全息互动酒吧等40 余项体验项目；百米高楼楼顶露台上，还有京西绝美的落日观景酒吧。 首钢园中的一高炉曾用来熔化铁水，享有"功勋炉"的美誉，园区在改造过程中，也最大限度保留了高炉 原有结构和外部工业建筑风貌。"我们把炉芯进行了完整保留，再以炉芯为基础，对整个炉体进行空间 改造，搭建出5个楼层，每层都分布着各种体验项目。"吕晓卓说。 开放一年以来，科幻乐园已经成为京西文旅新地标，全年累计十几万人次购票入园，还承接了北京近60 所中小学的研学活动，并有来自新加坡、德国、马来西亚、土耳其等地的国外游客专程到访。 不过，这一科幻空 ...

Syndax Pharmaceuticals (SNDX) 2025 Conference June 05, 2025 01:25 PM ET Speaker0 Good afternoon, everyone. Thank you for attending Jefferies Global Healthcare Conference. My name is Baozhi, a senior biotech analyst biotech team here. And please join me and welcome CEO, Mr. Michael Metzger CMO, Mr. Nick Batwood and COO, Mr. Steve Closter from Syndax Pharmaceuticals for this fireside chat session. Welcome. Speaker1 Thank you, Kelly. Speaker0 Maybe let's start with a high level question. Last year 2024 was a v ...

Key Takeaways PacBio beat first-quarter estimates with higher margins and a narrower adjusted operating loss. PACB's Revio and Vega systems drove adoption across research, clinical, and academic markets. PacBio targets $45 to $50 million in annual cost savings via restructuring by the end of 2025.Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, has been gaining from its continued product development. The optimism, led by decent first-quarter results, is expected to contribute fu ...

The Self-Storage sector in the U.S. has grown in size to a massive 2 billion square feet of space and over 33,000 facilities. The market remains fragmented, with the top 10 largest companies controlling around 36% of the totalIntroducing iREIT®Join iREIT® on Alpha today to get the most in-depth research that includes REITs, mREIT, Preferreds, BDCs, MLPs, ETFs, Builders, and Asset Managers. Our iREIT® Tracker provides data on over 250 tickers with our quality scores, buy targets, and trim targets.We recently ...

Allogene Therapeutics (ALLO) 2025 Conference June 04, 2025 04:55 PM ET Speaker0 We are very pleased to have the CEO of Allogene here with us, Doctor. David Chang. Allogene, despite the volatility of the markets, is obviously continuing to execute on the, I call it phase three, but pivotal phase two randomized study in a consolidation approach to first line DLBCL. And they have been working on that study, but also had some recent announcements on the last earnings. And so maybe it would be a good place to st ...

NeoGenomics (NEO) 2025 Conference June 04, 2025 02:00 PM ET Speaker0 Afternoon. I'm Tycho Peterson from the Life Science Tools Group. It's my pleasure to introduce our next company this afternoon, NeoGenomics. Tony, I'm going to maybe open it up with you. You've had a little bit of time in the CEO role here. Just talk about early learnings, how you're kind of thinking about stepping in, any big changes that need to happen? Speaker1 No. I think it's been a really good introductory period for me. I had the op ...

Key Takeaways Hyperfine received FDA clearance for its next-generation Swoop Portable MR Imaging system. HYPR's new Swoop system uses OptiVu AI to enhance image resolution, speed, and diagnostic utility. Hyperfine aims to expand clinical use with a compact, mobile design suited for diverse care settings.Hyperfine (HYPR) recently announced FDA 510(k) clearance for its next-generation Swoop Portable MR Imaging system. The clearance covers an entirely new portable magnetic resonance imaging (MRI) scanner pow ...

Core Insights - Johnson & Johnson announced significant findings from two Phase 3 studies demonstrating that DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based regimens lead to deep and sustained minimal residual disease (MRD) negativity and improved long-term progression-free survival (PFS) in newly diagnosed multiple myeloma patients, regardless of transplant eligibility [1][2][3] Group 1: Study Findings - In the Phase 3 PERSEUS study, over half of the patients maintained MRD negativity for 24 months or longer with the DARZALEX FASPRO® regimen [1][2] - The addition of DARZALEX FASPRO® to the standard treatment regimen (bortezomib, lenalidomide, and dexamethasone) resulted in a 55.8% sustained MRD negativity rate at the 10⁻⁵ threshold compared to 22.6% with the standard regimen alone [2][4] - The Phase 3 CEPHEUS study showed a 60% overall MRD negativity rate at the 10⁻⁵ threshold in transplant-ineligible patients, indicating significant treatment benefits across different patient populations [1][3] Group 2: Long-term Outcomes - At a median follow-up of 47.5 months, the PFS rate was 95.3% at 48 months for patients receiving the DARZALEX FASPRO® regimen, highlighting its effectiveness in delaying disease progression [2] - The study results indicated that 69% of patients treated with the DARZALEX FASPRO® regimen remained progression-free at 54 months, compared to 48% with the standard regimen [4][5] - The overall survival (OS) favored the DARZALEX FASPRO® group, with a hazard ratio of 0.66, suggesting a potential survival benefit [4] Group 3: Safety and Efficacy - The safety profiles of DARZALEX FASPRO® in the PERSEUS and CEPHEUS studies were consistent with previously known safety data, indicating a manageable safety profile [5] - The studies included diverse patient populations, including those considered high-risk for cytogenetic abnormalities, reinforcing the broad applicability of DARZALEX FASPRO® in treating multiple myeloma [3][5] - The consistent results across different studies support the role of DARZALEX FASPRO® as a cornerstone of frontline therapy for multiple myeloma [5]